Human IL-18 crystal structure
A novel human IL-18 native crystalline structure is identified.
1. A composition comprising human IL-18 protein in a crystalline form, wherein said protein has a cysteine to serine substitution at residue 38 of SEQ ID No: 1, and wherein the protein crystal is a primitive hexagonal (P6 1 ) crystal with unit cell dimensions a=71.4°, b=71.4°, c=88.7° α,β=90° and γ=120°.
2. The composition according to claim 1 wherein said human IL-1B protein is characterized by a β-trefoil fold.
3. A process of identifying an agonist or an antagonist of human IL-18 selected from the group consisting of: a peptide, a non-peptide and a small molecule;
wherein said agonist or antagonist is capable of enhancing, eliciting or blocking the interaction between human IL-18 and its receptor;
wherein said process comprises:
a) crystallizing the composition of claim 1 and determining the three-dimensional structural coordinates defined in Table 1;
b) introducing into a suitable computer program, said three-dimensional structural coordinates and having the program display said coordinates;
c) creating a three-dimensional model of a test compound in said computer program;
d) displaying and superimposing the model of said test compound onto the three-dimensional structural coordinates of the IL-18 protein;
e) assessing whether said test compound model is capable of affecting the interaction between IL-18 and its receptor; and
f) incorporating said test compound in an IL-18 activity assay and determining whether said test compound inhibits or enhances the biological activity of human IL-18 wherein said compounds are identified as agonists or antagonists.
4. A process of identifying an agonist or an antagonist capable of modifying the biological activity of the composition of claim 1 , wherein said process comprises:
carrying out an in vitro assay by introducing said compound into an IL-18 activity assay mixture; and determining whether said test compound inhibits or enhances the biological activity of human IL-18 receptor, wherein said compounds are identified as agonists or antagonists.